Each week in The Memo, we spotlight one emerging medtech company pushing the boundaries of what’s possible in patient care. This week, we’re doing something different. With LSI USA ‘26 just two weeks away, we’re featuring a special edition highlighting a select group of trailblazing companies across five major market segments, all of whom will take the stage in Dana Point.
This is only a snapshot of the companies presenting at LSI USA ‘26, but it offers a compelling preview of the innovation that will be on display.
*Note: All information included in this article is sourced from the LSI USA ‘26 Startup Profiles spreadsheet, Compass AI, and the LSI USA ‘26 Presenting Companies page.
Presenter: John Wong
Company Description: Fluid Biomed is developing the world's first bioabsorbable stent to treat brain aneurysms. The company's innovative polymer technology allows physicians the versatility of treating a wider variety of aneurysms more safely and efficiently.
Stage: Undisclosed
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Boston Scientific, Stryker, Terumo
Presenter: Saravana Kumar
Company Description: 4C Medical's AltaValve is a supra-annular transcatheter mitral valve replacement (TMVR) system. The AltaValve system is intended to streamline the procedure to replace degenerated mitral valves compared to current solutions.
Stage: Later Stage
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Medtronic, Boston Scientific, Abbott, Edwards
Presenter: Amir Soltanianzadeh
Company Description: StimCardio Medical is developing a breakthrough neuromodulation wearable therapy for AFib that combines peripheral neurostimulation with closed-loop, AI-enabled monitoring.
Stage: Series A
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Medtronic, Boston Scientific, Abbott, LivaNova
Presenter: Marc Zemel
Company Description: Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. The company's technology has been clinically validated and is used in 65 hospitals.
Stage: Series B
Commercial Status: Commercial (Revenue >5M)
Strategic Landscape: Fresenius, Masimo, Getinge
Presenter: Tarek Makansi
Company Description: StimAire's patented technology is an injectable, rice-grain-sized neurostimulator (combined with a small wearable) for treating obstructive sleep apnea, a $30B market. Replacing major surgery with a 15-minute injection is expected to lead to worldwide reimbursement and full market acceptance.
Stage: Series B
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Medtronic, Nihon Kohden, Natus, Novasom
Presenter: Per Langoe
Company Description: GT Medical's GammaTile Therapy is a targeted approach for delivering radiation to brain tumor cells. The company's technology minimizes complications while optimizing therapeutic efficacy. Placed by a neurosurgeon during resection, GammeTiles provide uniform radiation-source spacing to ensure even dose distribution.
Stage: Undisclosed
Commercial Status: Commercial (Revenue >10M)
Strategic Landscape: Varian, Accuray, Brainlab, Elekta, IBA
Presenter: Mordechai (Moty) Avisar
Company Description: Symphony Robotics is developing an AI-powered, MRI-guided micro-robotic platform that enables curved, minimally invasive access to deep and complex brain targets unreachable with conventional straight-line neurosurgical tools.
Stage: Series A
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Medtronic, J&J, Varian, Intuitive Surgical, Brainlab
Presenter: Katya Sverdlov
Company Description: JelikaLite is developing innovative neuromodulation therapies for pediatric neurological disorders. Its lead product, Cognilum, is an FDA Breakthrough-designated wearable device designed to reduce symptoms of autism spectrum disorder (ASD).
Stage: Undisclosed
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Boston Scientific
Presenter: Rick Thomson
Company Description: Sandia Medical Technologies is an emerging orthopedic company that has developed a replacement joint implant for the third most common site for osteoarthritis in the body. The implant, known as ZEPART, replaces the trapezium bone in the carpometacarpal joint, at the base of the thumb.
Stage: Seed
Commercial Status: Other (Pre-Revenue)
Strategic Landscape: J&J, Smith+Nephew, Stryker, Zimmer Biomet
Presenter: Luke Diehl
Company Description: Spark Spine is a medical technology company pioneering next-generation orthopedic implants. Using its patented EMP biomaterial, Spark products harvest electricity from the patient’s movement and use it to power unparalleled therapeutic and diagnostic advancements.
Stage: Seed
Commercial Status: Commercial (Pre-Revenue)
Strategic Landscape: J&J, Smith+Nephew, Stryker, Zimmer Biomet, Globus Medical
Presenter: Sydney Robinson
Company Description: Vessl is providing a solution for the hundreds of thousands of amputees who struggle to adapt to loss of limb. The company is designing an automatically adjusting prosthetic socket that redistributes pressure around the leg in response to changes in limb size.
Stage: Seed
Commercial Status: Commercial (Revenue <5M)
Strategic Landscape: Ossur, Ottobock, WillowWood, ARCH Medical Solutions
Presenter: Jeff Chandler
Company Description: KiriGenX is developing the first bioinductive collagen implant platform purpose-built for early-stage rotator cuff disease at the articular side. The technology delivers a biologic scaffold to support tendon healing in an underserved patient population and is advancing through a 510(k) pathway, with planned expansion into broader tendon repair indications.
Stage: Seed
Commercial Status: Pre-Clinical (Pre-Revenue)
Strategic Landscape: Arthrex, J&J, Stryker, Zimmer Biomet
Presenter: Lara Zibners
Company Description: Calla Lily Clinical Care has developed Callavid, a leak-free vaginal drug delivery platform that will revolutionize care for women. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage, which contributes to antimicrobial resistance (AMR).
Stage: Series A
Commercial Status: Clinical (Revenue <5M)
Strategic Landscape: Pfizer, Bayer, Merck
Presenter: Hanna Harkawy
Company Description: Ouli is an innovative telemedicine solution that enables cesarean scar therapy at home under remote specialist supervision. The system consists of a device equipped with a functional head that replicates manual scar mobilization techniques used by physiotherapists.
Stage: Seed
Commercial Status: Commercial (Pre-Revenue)
Strategic Landscape: CooperSurgical, Smith+Nephew, Procter & Gamble
Presenter: Laura Yecies
Company Description: Osteoboost is the first and only FDA-cleared, drug-free prescription treatment for low bone density. With a $30B market of 60M patients suffering from osteopenia and osteoporosis, Osteoboost is the first at-home device clinically proven to slow vertebral bone loss by 85%.
Stage: Series A
Commercial Status: Commercial (Revenue <5M)
Strategic Landscape: Terumo
Presenter: Liesl Nel-Themaat
Company Description: Noor Sciences is a company focused on improving IVF success rates through the development of non-invasive technologies. Its core innovation allows for the assessment of Embryo/Oocyte viability, helping clinicians select the most promising candidates for implantation.
Stage: Seed
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Hologic, Vitrolife, Vitromed
Presenter: Joana Cartocci
Company Description: Robeauté is developing a microrobot for novel therapies in hard-to-reach areas of the body. Designed specifically for the brain, at the service of neurosurgeons, the company’s microrobot will be able to freely navigate in other complex regions of the body to perform biopsies, collect precise anatomically localized data, and deliver therapies on site, at the right dosage.
Stage: Series B
Commercial Status: Pre-Clinical (Pre-Revenue)
Strategic Landscape: J&J, Roche, Novartis
Presenter: Donghee Kim
Company Description: LN Robotics is developing robotic systems and solutions to innovate percutaneous coronary intervention procedures. The platform provides precision, stability, and confidence to achieve better patient outcomes.
Stage: Series C
Commercial Status: Clinical (Revenue <5M)
Strategic Landscape: Medtronic, J&J, Siemens
Presenter: Jason Chan
Company Description: Agilis Robotics is advancing the field of endoluminal surgery with flexible, miniaturized robotic arms designed to navigate complex anatomy within the urinary and gastrointestinal tracts. The company’s proprietary robotic platform integrates seamlessly with standard endoscopes, offering enhanced precision, control, and dexterity.
Stage: Undisclosed
Commercial Status: Clinical (Pre-Revenue)
Strategic Landscape: Medtronic, J&J, Intuitive Surgical
Presenter: Kurt Azarbarzin
Company Description: Quantum Surgical is a pioneering medical robotics and artificial intelligence company that revolutionizes cancer treatment with innovative robotic-assisted solutions for minimally invasive tumor ablation. Its Epione platform is dedicated to the curative and early treatment of cancers.
Stage: Undisclosed
Commercial Status: Commercial (Revenue >20M)
Strategic Landscape: J&J, Varian, Intuitive Surgical
Each of the companies featured here has been selected to present at LSI USA ‘26, March 16th–20th. Join us in welcoming them to the event in Dana Point, CA, where they will share the latest updates on their technology and development.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy